Theravance Biopharma, Inc. Announces Resignation of Henrietta H. Fore as Director
January 03, 2018 at 04:32 pm IST
Share
On December 27, 2017, Ms. Henrietta H. Fore notified Theravance Biopharma, Inc. of her resignation as Director of the company, effective on December 31, 2017. Ms. Fore indicated her resignation was in connection with her appointment as Executive Director of the United Nations Children’s Fund (UNICEF), effective January 1, 2018 and not as the result of any disagreement with the Board or with the company’s management.
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders.
THERAVANCE BIOPHARMA, INC. 
